(Q44570349)

4 December 2017

title

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab (English)

1 reference

4 December 2017

1 reference

1 reference

K Weiss

1

1 reference

4 December 2017

I Steinbrugger

2

1 reference

4 December 2017

M Weger

3

1 reference

4 December 2017

N Ardjomand

4

1 reference

4 December 2017

R Maier

5

1 reference

4 December 2017

B J Wegscheider

6

1 reference

4 December 2017

A Wedrich

7

1 reference

4 December 2017

Y El-Shabrawi

8

1 reference

4 December 2017

publication date

23 January 2009

1 reference

4 December 2017

1 reference

4 December 2017

volume

23

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

1812-1818

1 reference

Macular microcirculation in cystoid maculopathy of diabetic patients

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Anti-tumour necrosis factor alpha treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Infliximab for chronic cystoid macular edema associated with uveitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Multiplex Bead Analysis of Vitreous Humor of Patients with Vitreoretinal Disorders

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin)

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Intravitreal bevacizumab for treatment of uveitic macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Inflammatory cystoid macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

The role of cytokines in the pathogenesis of inflammatory eye disease

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.388

7 January 2021

Identifiers

DOI

10.1038/EYE.2008.388

1 reference

4 December 2017

1 reference